Varun Mehta1, Ramit Mahajan1, Vandana Midha2, Vikram Narang3, Kirandeep Kaur4, Arshdeep Singh1, Anand Malhotra1, Aslam Parvez1, Ajit Sood1. 1. Department of Gastroenterology, Dayanand Medical College, Ludhiana, Punjab, India. 2. Department of Internal Medicine, Dayanand Medical College, Ludhiana, Punjab, India. 3. Department of Pathology, Dayanand Medical College, Ludhiana, Punjab, India. 4. Department of Pharmacology, Dayanand Medical College, Ludhiana, Punjab, India.
Abstract
OBJECTIVE: To assess impact of Direct Acting Antiviral (DAA) therapies for treatment of Hepatitis C Virus (HCV) genotypes 1, 3 and 4 in a real-world cohort from India. METHODS: Adults with chronic HCV infection treated with Sofosbuvir (SOF) and Ledipasvir (LDV) (genotypes 1 and 4) or SOF and Daclatasvir (DCV) (genotype 3), with or without Ribavirin (RBV) between December 2015 and December 2016 were included. The primary endpoint was Sustained Virological Response at Post-treatment Week 12 (SVR12). RESULTS: Of the 648 patients, 181 received SOF/LDV (65 with RBV) and 467 received SOF/DCV (135 with RBV). Most patients were males (65.4%), aged 41-60 years (49.4%) and treatment-naïve (92.6%). Genotype 3 (72.1%) was most common, followed by genotypes 1 (22.4%) and 4 (5.6%). Forty two percent patients (n = 271) had cirrhosis (112 patients were decompensated). SVR12 (modified intention-to-treat) was achieved by 98.1% of patients (512/522) (100% in genotypes 1 and 4, and 97.3% (362/372) in genotype 3). On intention to treat analysis, SVR12 was 88.1% (512/581) [genotype 1-96.8% (121/125), genotype 3-85.2%, genotype 4-93.5% (29/31)]. Seventy patients had treatment failure (non response in 6, virological breakthrough in 2, 10 patients relapsed, 2 died and 50 were lost to follow up). High SVR was observed regardless of HCV genotype, presence of cirrhosis or past history of treatment. No major adverse events warranting discontinuation of treatment were noted. CONCLUSIONS: DAA therapy for HCV genotypes 1, 3 and 4 achieves high SVR rates in all patients, including those with cirrhosis and previous non-responders.
OBJECTIVE: To assess impact of Direct Acting Antiviral (DAA) therapies for treatment of Hepatitis C Virus (HCV) genotypes 1, 3 and 4 in a real-world cohort from India. METHODS: Adults with chronic HCV infection treated with Sofosbuvir (SOF) and Ledipasvir (LDV) (genotypes 1 and 4) or SOF and Daclatasvir (DCV) (genotype 3), with or without Ribavirin (RBV) between December 2015 and December 2016 were included. The primary endpoint was Sustained Virological Response at Post-treatment Week 12 (SVR12). RESULTS: Of the 648 patients, 181 received SOF/LDV (65 with RBV) and 467 received SOF/DCV (135 with RBV). Most patients were males (65.4%), aged 41-60 years (49.4%) and treatment-naïve (92.6%). Genotype 3 (72.1%) was most common, followed by genotypes 1 (22.4%) and 4 (5.6%). Forty two percent patients (n = 271) had cirrhosis (112 patients were decompensated). SVR12 (modified intention-to-treat) was achieved by 98.1% of patients (512/522) (100% in genotypes 1 and 4, and 97.3% (362/372) in genotype 3). On intention to treat analysis, SVR12 was 88.1% (512/581) [genotype 1-96.8% (121/125), genotype 3-85.2%, genotype 4-93.5% (29/31)]. Seventy patients had treatment failure (non response in 6, virological breakthrough in 2, 10 patients relapsed, 2 died and 50 were lost to follow up). High SVR was observed regardless of HCV genotype, presence of cirrhosis or past history of treatment. No major adverse events warranting discontinuation of treatment were noted. CONCLUSIONS: DAA therapy for HCV genotypes 1, 3 and 4 achieves high SVR rates in all patients, including those with cirrhosis and previous non-responders.
Entities:
Keywords:
DAA, Direct Acting Antiviral; DCV, Daclatasvir; EASL, European Association of Study of the Liver (EASL); ETR, End of Treatment Response; HBV, Hepatitis B; HCC, Hepatocellular Carcinoma; HCV, Hepatitis C Virus; HIV, Human Immunedeficiency Virus; ITT, intention to treat; LDV, ledipasvir; RBV, Ribavirin; RVR, Rapid Virological Response; SOF, Sofosbuvir; SVR, Sustained Virological Response; SVR12, sustained virological response at Post-treatment Week 12; direct acting antivirals; hepatitis C; mITT, modified Intention-to-Treat; real life experience
Authors: Javier Crespo; Jose Luis Calleja; Inmaculada Fernández; Begoña Sacristan; Belén Ruiz-Antorán; Javier Ampuero; Marta Hernández-Conde; Javier García-Samaniego; Francisco Gea; Maria Buti; Joaquin Cabezas; Sabela Lens; Rosa Maria Morillas; Jose Ramon Salcines; Juan Manuel Pascasio; Juan Turnes; Federico Sáez-Royuela; Juan Arenas; Diego Rincón; Martin Prieto; Francisco Jorquera; Juan Jose Sanchez Ruano; Carmen A Navascués; Esther Molina; Adolfo Gallego Moya; José Maria Moreno-Planas Journal: Clin Gastroenterol Hepatol Date: 2017-02-24 Impact factor: 11.382
Authors: Sajid Ali; Ayaz Ahmad; Raham Sher Khan; Sanaullah Khan; Muhammad Hamayun; Sumera Afzal Khan; Amjad Iqbal; Abid Ali Khan; Abdul Wadood; Taj Ur Rahman; Ali Hydar Baig Journal: Adv Virol Date: 2014-02-26
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: S S Solomon; D Boon; S Saravanan; A K Srikrishnan; C K Vasudevan; P Balakrishnan; D Persaud; S C Ray; S Mehta; S H Mehta Journal: Virusdisease Date: 2019-12-07
Authors: Massimo Giuseppe Colombo; Erkin Isakovich Musabaev; Umed Yusupovich Ismailov; Igor A Zaytsev; Alexander V Nersesov; Igor Anatoliyevich Anastasiy; Igor Alexandrovich Karpov; Olga A Golubovska; Kulpash S Kaliaskarova; Ravishankar Ac; Sanjay Hadigal Journal: World J Gastroenterol Date: 2019-08-07 Impact factor: 5.742
Authors: Michael J Zoratti; Ayesha Siddiqua; Rita E Morassut; Dena Zeraatkar; Roger Chou; Judith van Holten; Feng Xie; Eric Druyts Journal: EClinicalMedicine Date: 2020-01-05